Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$32.38
-0.27-0.83%
At close: -
$33.10
0.722.22%
After Hours: 6:53 PM EDT
Comments
Loading...
CRISPR Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRSP | Benzinga
CRISPR Therapeutics AG has a consensus price target of $71.68 based on the ratings of 28 analysts. The high is $120 issued by Truist Securities on February 12, 2025. The low is $30 issued by TD Cowen on December 11, 2023. The 3 most-recent analyst ratings were released by Citigroup, Morgan Stanley, and Evercore ISI Group on February 18, 2025, February 14, 2025, and February 14, 2025, respectively. With an average price target of $71 between Citigroup, Morgan Stanley, and Evercore ISI Group, there's an implied 114.50% upside for CRISPR Therapeutics AG from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Morgan Stanley
Evercore ISI Group
Goldman Sachs
JMP Securities
1calculated from analyst ratings
Analyst Ratings for CRISPR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/19/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt29% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/18/2025 | Buy Now | 147.73% | Citigroup | Yigal Nochomovitz53% | $89 → $82 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | -3.32% | Morgan Stanley | Terence Flynn67% | $30 → $32 | Maintains | Underweight | Get Alert |
| 02/14/2025 | Buy Now | 199.09% | Evercore ISI Group | Liisa Bayko70% | $60 → $99 | Upgrade | In-Line → Outperform | Get Alert |
| 02/13/2025 | Buy Now | 72.21% | Goldman Sachs | Salveen Richter39% | $66 → $57 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | 159.82% | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2025 | Buy Now | 48.04% | Stifel | Benjamin Burnett43% | $53 → $49 | Maintains | Hold | Get Alert |
| 02/13/2025 | Buy Now | 96.37% | HC Wainwright & Co. | Mitchell Kapoor44% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 153.78% | Chardan Capital | Geulah Livshits44% | $94 → $84 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 262.54% | Truist Securities | Joon Lee77% | $100 → $120 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 45.02% | RBC Capital | Luca Issi39% | $53 → $48 | Maintains | Sector Perform | Get Alert |
| 02/12/2025 | Buy Now | 153.78% | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 69.18% | Barclays | Gena Wang50% | $55 → $56 | Maintains | Equal-Weight | Get Alert |
| 02/03/2025 | Buy Now | 96.37% | HC Wainwright & Co. | Mitchell Kapoor44% | → $65 | Initiates | → Buy | Get Alert |
| 01/14/2025 | Buy Now | 153.78% | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 156.8% | B of A Securities | Geoff Meacham24% | $98 → $85 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 159.82% | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/10/2024 | Buy Now | 183.99% | Chardan Capital | Geulah Livshits44% | $94 → $94 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 60.12% | RBC Capital | Luca Issi39% | $53 → $53 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 66.16% | Barclays | Gena Wang50% | $59 → $55 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | 153.78% | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 10/04/2024 | Buy Now | 60.12% | RBC Capital | Luca Issi39% | $60 → $53 | Maintains | Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | 202.11% | Truist Securities | Joon Lee77% | $120 → $100 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt29% | — | Reiterates | → Neutral | Get Alert |
| 08/06/2024 | Buy Now | 78.25% | Stifel | Benjamin Burnett43% | $60 → $59 | Maintains | Hold | Get Alert |
| 08/06/2024 | Buy Now | 78.25% | Barclays | Gena Wang50% | $67 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | 81.27% | RBC Capital | Luca Issi39% | $66 → $60 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 183.99% | Chardan Capital | Geulah Livshits44% | $112 → $94 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 153.78% | Needham | Gil Blum48% | $88 → $84 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | — | Assumes | → Neutral | Get Alert |
| 06/27/2024 | Buy Now | 165.86% | Needham | Gil Blum48% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 217.22% | Piper Sandler | Edward Tenthoff13% | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 165.86% | Needham | Gil Blum48% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 153.78% | Citigroup | Yigal Nochomovitz53% | $89 → $84 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 187.01% | Oppenheimer | Jay Olson61% | $102 → $95 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 159.82% | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | 96.37% | Wells Fargo | Yanan Zhu11% | $70 → $65 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt29% | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 102.42% | Barclays | Gena Wang50% | $80 → $67 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 165.86% | Needham | Gil Blum48% | $90 → $88 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 57.1% | Baird | Jack Allen 37% | $46 → $52 | Maintains | Neutral | Get Alert |
| 04/18/2024 | Buy Now | 168.88% | Citigroup | Yigal Nochomovitz53% | $88 → $89 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 171.9% | Needham | Gil Blum48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 199.09% | Mizuho | Salim Syed44% | $82 → $99 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 45.02% | Morgan Stanley | Terence Flynn67% | $46 → $48 | Maintains | Underweight | Get Alert |
| 02/22/2024 | Buy Now | 99.4% | RBC Capital | Luca Issi39% | $57 → $66 | Maintains | Sector Perform | Get Alert |
| 02/22/2024 | Buy Now | 111.48% | Wells Fargo | Jim Birchenough61% | $55 → $70 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 141.69% | Barclays | Gena Wang50% | $61 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 238.37% | Chardan Capital | Geulah Livshits44% | $110 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 171.9% | Needham | Gil Blum48% | $88 → $90 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Initiates | → Peer Perform | Get Alert |
| 12/11/2023 | Buy Now | 72.21% | RBC Capital | Luca Issi39% | $50 → $57 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | Buy Now | 383.38% | Truist Securities | Joon Lee77% | $220 → $160 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 84.29% | Barclays | Gena Wang50% | $56 → $61 | Maintains | Equal-Weight | Get Alert |
| 12/11/2023 | Buy Now | -9.37% | TD Cowen | Tyler Van Buren47% | → $30 | Downgrade | Market Perform → Underperform | Get Alert |
| 12/11/2023 | Buy Now | 141.69% | JMP Securities | Silvan Tuerkcan44% | $74 → $80 | Maintains | Market Outperform | Get Alert |
| 12/11/2023 | Buy Now | 165.86% | Needham | Gil Blum48% | $85 → $88 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 564.65% | Truist Securities | Joon Lee77% | → $220 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | 147.73% | Mizuho | Salim Syed44% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | Buy Now | 123.56% | JMP Securities | Silvan Tuerkcan44% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | 26.89% | Morgan Stanley | Terence Flynn67% | $43 → $42 | Maintains | Underweight | Get Alert |
| 11/07/2023 | Buy Now | 51.06% | RBC Capital | Luca Issi39% | $55 → $50 | Maintains | Sector Perform | Get Alert |
| 11/07/2023 | Buy Now | 156.8% | Needham | Gil Blum48% | $88 → $85 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 165.86% | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | 165.86% | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt29% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/27/2023 | Buy Now | 147.73% | Mizuho | Salim Syed44% | → $82 | Initiates | → Buy | Get Alert |
| 08/18/2023 | Buy Now | 111.48% | Citigroup | Yigal Nochomovitz53% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/17/2023 | Buy Now | 111.48% | Citigroup | Yigal Nochomovitz53% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2023 | Buy Now | 29.91% | Morgan Stanley | Terence Flynn67% | $42 → $43 | Maintains | Underweight | Get Alert |
| 08/10/2023 | Buy Now | 208.16% | Oppenheimer | Jay Olson61% | → $102 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 90.33% | Credit Suisse | Richard Law43% | $62 → $63 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 126.59% | EF Hutton | Tony Butler42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 165.86% | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 232.33% | Chardan Capital | Geulah Livshits44% | $123 → $110 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 123.56% | JMP Securities | Silvan Tuerkcan44% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 165.86% | Needham | Gil Blum48% | $82 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/09/2023 | Buy Now | 123.56% | JMP Securities | Silvan Tuerkcan44% | $70 → $74 | Maintains | Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 126.59% | EF Hutton | Tony Butler42% | → $75 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 93.35% | Barclays | Gena Wang50% | $61 → $64 | Maintains | Equal-Weight | Get Alert |
| 05/30/2023 | Buy Now | 126.59% | William Blair | Sami Corwin6% | → $75 | Reinstates | → Outperform | Get Alert |
| 05/23/2023 | Buy Now | 111.48% | Citigroup | Yigal Nochomovitz53% | $55 → $70 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | 26.89% | Morgan Stanley | Terence Flynn67% | $39 → $42 | Maintains | Underweight | Get Alert |
| 05/09/2023 | Buy Now | 51.06% | RBC Capital | Luca Issi39% | → $50 | Reiterates | → Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | 111.48% | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 05/09/2023 | Buy Now | 87.31% | Credit Suisse | Richard Law43% | $65 → $62 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | 93.35% | Stifel | Benjamin Burnett43% | $69 → $64 | Maintains | Hold | Get Alert |
| 05/09/2023 | Buy Now | 147.73% | Needham | Gil Blum48% | → $82 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 147.73% | Needham | Gil Blum48% | → $82 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 111.48% | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 04/17/2023 | Buy Now | 126.59% | EF Hutton | Tony Butler42% | → $75 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 117.52% | Cantor Fitzgerald | Olivia Brayer60% | → $72 | Initiates | → Overweight | Get Alert |
| 04/03/2023 | Buy Now | 126.59% | EF Hutton | Tony Butler42% | → $75 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | 32.93% | Bernstein | William Pickering41% | → $44 | Initiates | → Market Perform | Get Alert |
| 03/18/2023 | Buy Now | 66.16% | Citigroup | Yigal Nochomovitz53% | $63 → $55 | Maintains | Neutral | Get Alert |
| 03/07/2023 | Buy Now | 38.97% | Baird | Jack Allen 37% | → $46 | Initiates | → Neutral | Get Alert |
| 02/27/2023 | Buy Now | 111.48% | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 02/27/2023 | Buy Now | 17.82% | Morgan Stanley | Terence Flynn67% | $37 → $39 | Maintains | Underweight | Get Alert |
| 02/23/2023 | Buy Now | 208.34% | Oppenheimer | Jay Olson61% | $110 → $102.06 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | 271.6% | Chardan Capital | Geulah Livshits44% | $153 → $123 | Maintains | Buy | Get Alert |
FAQ
What is the target price for CRISPR Therapeutics (CRSP) stock?
The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Cantor Fitzgerald on February 19, 2025. The analyst firm set a price target for $0.00 expecting CRSP to fall to within 12 months (a possible -100.00% downside). 43 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Cantor Fitzgerald, and CRISPR Therapeutics reiterated their neutral rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on February 14, 2025 when Evercore ISI Group raised their price target to $99. Evercore ISI Group previously had an in-line for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $0.00 to $0.00. The current price CRISPR Therapeutics (CRSP) is trading at is $33.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.